Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein S15a pseudogene 28 (RPS15AP28)
- Target
- RPS15AP28
- Molecular classification
- Pseudogene, Processed pseudogene, Ribosomal protein pseudogene
01
Overview
Ribosomal protein S15a pseudogene 28 (RPS15AP28) is a processed pseudogene in the human genome, meaning it structurally resembles the functional ribosomal protein S15a gene (RPS15A) but does not encode a protein. Instead, its transcribed RNA may act as a competitive endogenous RNA (ceRNA), binding microRNAs that would otherwise suppress the parental gene. This function can modulate the expression of RPS15A and possibly impact protein synthesis rates in cells. Studies have shown upregulation of related ribosomal protein pseudogenes, including RPS15AP28, correlates with aggressive cancer behavior and poor prognosis, likely through enhanced ribosome biogenesis and cell proliferation. While RPS15AP28 itself is not a classical drug target, emerging RNA-focused drug discovery may attempt to modulate its ceRNA activity to restore normal regulation of ribosomal protein genes in cancer
- Other names
- RPS15A_16_1058RPS15AP28HGNC: 36381NCBI Gene: 100132400Ensembl: ENSG00000229197
02
Mechanism of action
Modulation of RNA levels (e.g., blockade or degradation of RPS15AP28 mRNA to free up miRNAs for parental gene targeting)
03
Biological functions
Competitive endogenous RNA (ceRNA) regulation (sponging miRNAs targeting RPS15A or related ribosomal proteins)Possible regulation of parental ribosomal protein gene expressionModulation of post-transcriptional gene control via RNA interactions
04
Disease associations
Cancer (upregulation linked with poorer survival and lethal phenotype, especially in pancreatic cancer and other solid tumors)Possible oncogenesis and contribution to tumor cell proliferation via ceRNA function
05
Safety considerations
No established safety profile; as a pseudogene, direct targeting may have unknown risks and off-target RNA effects; essentiality of ribosomal protein homeostasis in normal cells
06
Interacting drugs
None directly established; exploratory approaches may target RPS15AP28 RNA with small molecules or RNA modifiers, but no approved or well-characterized drugs
07
Biomarkers
Upregulation of RPS15AP28 pseudogene mRNA may indicate high-risk cancer phenotypes or poor prognosis in select tumor types (e.g., pancreatic cancer)
Beyond the preview
Go deeper on Ribosomal protein S15a pseudogene 28 (RPS15AP28).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ribosomal protein S15a pseudogene 28 (RPS15AP28).